Table 3.
Author/year of publication | Study design | Laboratory technique | Number of patients | Cut-off value | Trimester 1 | Trimester 2 | Trimester 3 | Conclusion | |
---|---|---|---|---|---|---|---|---|---|
1 | Touitou 1989 [6] | cross-sectional | IRMA, CIS-Bio International, Gif-Sur-Yvette, France | T1 n = 32; T2 n = 32; T3 n = 36 | <25 | 11.1 ± 4.2 mean ± SD |
14.2 ± 5.1 | 17.0 ± 5.0 | None above cut-off value |
2 | Schlageter 1998 [7] | longitudinal | ELSA-CA 15-3 (CIS-Bio International), Gif-Sur-Yvette, France | n = 12 | <30 | 9.3 ± 4.0 (mean ± SD) 5 to 15 (range) |
14.1 ± 4.1 10 to 22.8 |
16.5 ± 4.1 8.8 to 24.2 |
None above cut-off value |
3 | Botsis 1999 [8] | cross-sectional | EIA, Tumor markers CA 153, Abbott AXSYM system, Abbott Park, Il, USA | T1 n = 20; T2 n = 29; T3 n = 26 | <33 | 18.0 (median) 14 to 30 (range) |
20 1.0 to 34 |
22 12 to 41 |
5%, 10% and 20% above cut-off value, in the 3 trimesters respectively |
4 | Cheli 1999 [9] | cross-sectional | Bayer Immuno 1 CA 15-3 assay, Tarrytown, New York, USA) | T1 n = 32; T2 n = 5; T3 n = 53 | <35 | 16.76 (mean) | - | 20.78 | 3.3% above cut-off value |
5 | Bon 2001 [10] | cross-sectional | Enzymun-Test CA 15-3 (Boehringer, Mannheim, Germany) | T1 n = 127; T2 n = 192; T3 n = 47 | Not stated | 14.0 (median) 5.0 to 32 (range) |
15.0 6.0 to 40 |
26.0 9 to 56 |
Raised above cut-off value, percentage not stated |
6 | Ercan 2011 [11] | longitudinal | Modular Analytics E 170 Module (Roche diagnostics), Basel, Switserland. | n = 30 | <25 | 17.5 (median) 7.6 to 39.3 (range) |
19.7 10.4 to 39 |
18.3 7 to 38.6 |
16% above cut-off value |
SD, standard deviation; T, trimester.